First Oncolytic Viral Therapy for Melanoma
- PMID: 26552414
- DOI: 10.1158/2159-8290.CD-NB2015-158
First Oncolytic Viral Therapy for Melanoma
Abstract
The FDA has approved talimogene laherparepvec, or T-VEC, to treat surgically unresectable skin and lymph node lesions in patients with advanced melanoma. T-VEC is the first oncolytic viral therapy to gain regulatory endorsement, based on data from the OPTiM study.
©2016 American Association for Cancer Research.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical